Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase II, Multicenter, Four-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease

Status
Closed
Cancer Type
Lung Cancer
Trial Phase
Phase II
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCT ID
NCT02414139
Protocol IDs
CINC280A2201 (primary)
NCI-2015-01536
2014-003850-15
Study Sponsor
Novartis Pharmaceuticals Corporation

Summary

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult

patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) after one or two

prior lines of systemic therapy for advanced/metastatic disease as measured by overall

response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.

Treatment Sites in Georgia

Northwest Georgia Oncology Centers - Marietta


340 Kennestone Hospital Boulevard
Suite 200
Marietta, GA 30060
770-281-5131
www.ngoc.com

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.